HU-308
This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (November 2021) |
Legal status | |
---|---|
Legal status |
|
Pharmacokinetic data | |
Metabolism | Liver |
Excretion | Kidneys |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
HU-308 (also known as onternabez, HU308, PPP-003 and ARDS-003) is a
CB1 receptor.[1][2][3] The synthesis and characterization of HU-308 took place in the laboratory of Raphael Mechoulam at the Hebrew University of Jerusalem (the HU in HU-308) in the late 1990s. The pinene dimethoxy-DMH-CBD derivative HU-308 was identified as a potent peripheral CB2-selective agonist in in vitro and animal studies in 1990[1] and 1999.[2]
Legal status
Tetra Bio-Pharma owns the intellectual property rights to HU-308.[4][5]
HU-308 is non-psychoactive and not scheduled at the federal level in the United States.[6] It is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess there.[7]
References
- ^ .
- ^ PMID 10588688.
- ^ "Properties of HU-308 ~ Formula C27H42O3". Pitt Quantum Repository. University of Pittsburgh Department of Chemistry.
- ^ US 9549906, Lynch M, Kelly M, "Composition & Methods for Treatment of Ocular Inflammation &/or Pain", issued 24 January 2017, assigned to Panag Pharma, Inc.
- ^ "Tetra Bio-Pharma Closes the Acquisition of Panag Pharma". May 2019.
- ^ "21 CFR — Schedules of controlled substances §1308.11 Schedule I." Archived from the original on 2009-08-27. Retrieved 2014-12-17.
- ^ "Chapter 893 - Drug abuse prevention and control". Florida Statutes.